Pterygium

25

Pipeline Programs↗

1

Active Trials↗

10

Companies Involved↗

Pterygium is an emerging landscape with 25 programs across 10 companies. The most active players are Suzhou Raymon Pharmaceuticals Company, Ltd., Gynecologic Oncology Group, Boehringer Ingelheim. 9 therapies are approved with 5 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

49/100

Pipeline Velocity

0/100

Mech. Concentration

33/100

Completion Rate

96/100

Attrition Rate

3/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Suzhou Raymon Pharmaceuticals Company, Ltd.

1 program

Gynecologic Oncology Group

1 program

Boehringer Ingelheim

1 program

AbbVie

2 programs

Cloudbreak Therapeutics, LLC

1 program

Roche

2 programs

Pipeline

Programs by Phase

Preclinical5

Fluorometholone

AbbVie

Tripterygium

Nanjing University School of Medicine

Post-Operative Application of Csa

Benha University

Intra-Operative Application of MMC

Benha University

Enteral Nutrition

Jagiellonian University

Phase 11

Intralesional Ranibizumab

Universiti Sains Malaysia

Phase 25

Mitomycin C

Gynecologic Oncology Group

Ranibizumab

Roche

RMP-A03 - Dose 2

Suzhou Raymon Pharmaceuticals Company, Ltd.

Dipyridamole

Boehringer Ingelheim

Local Injection of Bevacizumab

University of Alabama at Birmingham

Phase 35

Bevacizumab

Bio-Thera Solutions

Mycophenolate Mofetil

Roche

Topical Antihistamine and Vasoconstrictor

Khon Kaen University

Intralesional Injection of Bevacizumab

Khon Kaen University

CBT-001

Cloudbreak Therapeutics, LLC

Approved9

Prednisolone Acetate

Novartis

Mitomycin

UroGen Pharma Ltd.

Methotrexate

Alnylam Pharmaceuticals

Tripterygium Wilfordii

Zhi-Hong Liu, M.D.

PRO-155

Laboratorios Sophia S.A de C.V.

Analysis

Modality Breakdown

86%

Small molecule

32 of 37 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 37 classified programs, each share of the total. Modality classified for 100% of 37 pipeline programs.

Analysis

Trial Status

35

clinical trials

Completed24 · 69%

Unknown status9 · 26%

Withdrawn1 · 3%

Active, not recruiting1 · 3%

Clinical Trials

Trial Activity

35 trials

A Clinical Trial on Safety and Efficacy of CBT-001 in Patients With Pterygium

Active, not recruiting·CCloudbreak Therapeutics, LLC·Phase 3·NCT05456425·660 enrolled

RMP-A03 Ocular Suspension in Patients With Pterygium

Completed·SSuzhou Raymon Pharmaceuticals Company, Ltd.·Phase 2·NCT05794204·77 enrolled

Dextenza for Post-operative Treatment of Pterygium

Completed·BBrandon Eye Associates, PA·Phase 4·NCT04351737·20 enrolled

The Effect of Bevacizumab (Avastin) on Pterygium

Completed·UUniversity of Alabama at Birmingham·Phase 2·NCT00592176·5 enrolled

Evaluation of Tranilast to Treat Pterygium Before Excision

Completed·GGildasio Castello de Almeida Junior·Phase 3·NCT01003613·32 enrolled

Bevacizumab Injection for Recurrent Pterygium

Completed·IInstituto de Oftalmología Fundación Conde de Valenciana·N/A·NCT02007174·38 enrolled

Efficacy and Safety of PRO-155 on Inflammation of the Conjunctival Surface in Subjects With Grade I-III Pterygium vs Placebo.

Completed·LLaboratorios Sophia S.A de C.V.·Phase 4·NCT03521791·166 enrolled

The Use of Lidocaine Gel Versus Subconjunctival Xylocaine Injection in Pterygium Excision

Completed·VVrije Universiteit Brussel·Phase 4·NCT05978687·41 enrolled

Randomized Controlled Trial of Subconjunctival Bevacizumab Injection in Impending Recurrent Pterygium

Completed·RRamathibodi Hospital·N/A·NCT01288404·80 enrolled

Intralesional Ranibizumab on Pterygium Vascularity, Size and Recurrence Rate: a Pilot Study

Completed·UUniversiti Sains Malaysia·Phase 2/3·NCT02342392·36 enrolled

Safety Study of Avastin Used as Adjunctive Therapy in Pterygium Surgery

Completed·TThe University of Texas Health Science Center, Houston·Phase 2·NCT01115517·51 enrolled

CsA vs MMC for Preventing Pterygium Recurrence

Completed·—·N/A·NCT06944132·40 enrolled

Effect of Bromfenac on Pain Related to Pterygium Surgery

Completed·ZZhongshan Ophthalmic Center, Sun Yat-sen University·Phase 4·NCT04022811·60 enrolled

Safety and Efficacy of CBT-001 Ophthalmic Solution in Patients With Pterygium

Completed·CCloudbreak Therapeutics, LLC·Phase 2·NCT03049852·75 enrolled

Effectiveness and Safety of Yisaipu Combined With Tripterygium Wilfordii for Active RA

Completed·PPeking Union Medical College Hospital·Phase 4·NCT03589833·504 enrolled

Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)